GreggL.SemenzaMD
Pediatrics • Baltimore, MDProfessor of Pediatrics, Professor of Radiation Oncology and Molecular
Are you Dr. Semenza?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 N Caroline St
Baltimore, MD 21287Phone+1 410-955-3071
Summary
- Dr. Gregg Semenza, MD is a pediatrician in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland and North Carolina. He is a Professor of Pediatrics at Professor of Radiation Oncology and Molecular.
Education & Training
Perelman School of Medicine at the University of PennsylvaniaClass of 1984
Certifications & Licensure
MD State Medical License 1990 - 2025
NC State Medical License 1984 - 1999
American Board of Medical Genetics and Genomics Clinical Genetics
Publications & Presentations
PubMed
- 1 citationsVEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept.Deepti Sharma, Evan Lau, Yu Qin, Kathleen Jee, Murilo Rodrigues
Proceedings of the National Academy of Sciences of the United States of America. 2024-11-12 - Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy.Walter Jackson Iii, Yongkang Yang, Shaima Salman, Dominic Dordai, Yajing Lyu
Science Advances. 2024-08-30 - 2 citationsHypoxia-inducible factor 1 recruits FACT and RNF20/40 to mediate histone ubiquitination and transcriptional activation of target genes.Yajing Lyu, Yongkang Yang, Varen Talwar, Haiquan Lu, Chelsey Chen
Cell Reports. 2024-04-23
Press Mentions
Researchers Identify Why Some Don’t Respond to Anti-VEGF Drugs for AMDNovember 13th, 2024- People of the U: Elizabeth WicksJanuary 18th, 2022
- 146th Annual Meeting of the American Neurological Association to Focus on Research and Development of Neurologic Disease TherapeuticsOctober 5th, 2021
- Join now to see all
